SavedAdd your journal

Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2011 / Cilt: 25 - Sayı: 3

A comparison of ESHAP with R-ESHAP chemotherapy regimen as mobilizing regimen in hodgkin lymphoma and non-hodgkin lymphoma patients

Hodgkin lenfoma ve non-hodgkin lenfoma hastalarında ESHAP ve R-ESHAP kemoterapilerinin mobilizasyon etkinliği açısından karşılaştırılması

Serkan OCAKÇI
Seçkin ÇAĞIRGAN
MURAT TOMBULOĞLU
Güray SAYDAM
Pages
155–161
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusıon: Rituximab addition to ESHAP regimen may overcome negative effects of low platelet counts before aphaeresis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years great advance has been succeeded in therapy of lymphomas.
📊
Key Findings & Data:Rituximab has become a gold standard of CD20 positive non-Hodgkin lymphomas.
💡
Conclusion & Impact:Conclusıon: Rituximab addition to ESHAP regimen may overcome negative effects of low platelet counts before aphaeresis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In recent years great advance has been succeeded in therapy of lymphomas. Rituximab has become a gold standard of CD20 positive non-Hodgkin lymphomas. Its effects on mobilization have not been studied sufficiently. Methods: We evaluated 84 Hodgkin lymphoma and non-Hodgkin lymphoma patients who were mobilized with ESHAP or R-ESHAP chemotherapy regimens in 11 years. Results: We found out that R-ESHAP regimen was not significantly inferior to ESHAP regimen. Conclusıon: Rituximab addition to ESHAP regimen may overcome negative effects of low platelet counts before aphaeresis.

Özet

Amaç: Geçtiğimiz yıllarda lenfomaların tedavisinde büyük ilerleme gerçekleştirilmiştir. CD20 pozitif non-Hodgkin lenfomaların tedavisinde Rituksimab altın standart olmuştur. Mobilizasyon üzerine olan etkileri üzerine yeterli çalışma yapılmamıştır. Gereç ve yöntem: 11 yıllık sürede ESHAP veya R-ESHAP ile mobilize edilmiş 84 Hodgkin lenfoma ve non-Hodgkin lenfoma hastasını değerlendirdik. Bulgular: R-ESHAP rejiminin istatistiksel olarak ESHAP rejiminden daha az etkili olmadığını bulduk. Sonuç: Aferez öncesi düşük trombosit sayısının engrafman üzerine oluşturduğu olumsuz etki ESHAP rejimine rituksimab eklenmesi ile ortadan kaldırılabilir.

🔖

Cite This Article

OCAKÇI, S., ÇAĞIRGAN, S., TOMBULOĞLU, M., SAYDAM, G. (2011). A comparison of ESHAP with R-ESHAP chemotherapy regimen as mobilizing regimen in hodgkin lymphoma and non-hodgkin lymphoma patients. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 25 - Sayı: 3, 155–161. https://ajindex.com/articles/175324

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 2005;23: 6508
  2. Hahn T, Wolff SN, Czuczman M, et al. ASBMT Expert Panel: the role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence- based review. Biol Blood Marrow Transplant 2001;7: 308–331
  3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non- Hodgkin’s lymphoma. N Engl J Med 1995;333:1540– 1545
  4. Prince HM, Imrie K, Crump M, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880–889
  5. Pfreundschuh M, Rueffer U, Lathan B, et al. Dexa- BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 1994;12: 580–586
  6. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini- BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. British Journal of Haematology 2001;113:161–171
  7. Alvarez I, Sureda A, Arranz R, et al. Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin’s Lymphoma Patients. ASH Annual Meeting Abstracts 2005;106:2676
  8. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non- Hodgkin’s lymphoma. J Clin Oncol 1999;17: 3776- 3785
  9. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with highdose Ara-C and dexamethasone (DHAP). Blood 1988;71: 117–122
  10. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP– an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-ye